Effectiveness of leukocyte interferon-α treatment in patients with chronic hepatitis C not responsive to recombinant interferon

Digestive Diseases and Sciences

Volumn 43, Issue 10, 1998, Pages 2173-2176

  Scotto, Gaetano ^b   Grimaldi, Maria ^a  

^a Alfa Wassermann SpA   (Italy)

^b NONE

Author keywords

Chronic active hepatitis; Hepatitis C; Interferon

Indexed keywords

ALANINE AMINOTRANSFERASE; ALPHA INTERFERON; ALPHA INTERFERON A; RECOMBINANT INTERFERON;

ADULT; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ARTICLE; CHRONIC HEPATITIS; CLINICAL ARTICLE; DRUG EFFICACY; FEMALE; FOLLOW UP; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; MALE; PRIORITY JOURNAL; RELAPSE; RETREATMENT; TREATMENT FAILURE; TREATMENT INDICATION; TREATMENT OUTCOME;

ADULT; ALANINE TRANSAMINASE; ASPARTATE AMINOTRANSFERASES; FEMALE; FOLLOW-UP STUDIES; HEPACIVIRUS; HEPATITIS C, CHRONIC; HUMANS; INTERFERON TYPE I, RECOMBINANT; INTERFERON-ALPHA; MALE; RNA, VIRAL; TIME FACTORS; TREATMENT FAILURE; TREATMENT OUTCOME;

EID: 0031766895     PISSN: 01632116     EISSN: None     Source Type: Journal    
DOI: 10.1023/A:1026693901012     Document Type: Article

References (32)

1. Yatsubshi M, Inone O: Short and long-term effects of interferon on serum markers of hepatitis C virus replication. J Gastroenterol Hepatol 8:1-6, 1993
2. Dusheiko GM, Rizzetto M: The management of chronic hepatitis C. Synopses in Viral Hepatitis 10-14:14-15, 1993
3. Takahashi M, Yamada G, Muyamoto R: Natural course of chronic hepatitis C. Am J Gastroenterol 88:240-243, 1993
4. Bresci G, Parisi G, Banti S, Capzia A: Retreatment of interferon-resistant patients with chronic hepatitis with interferon α. J Viral Hepatitis 2:155-158, 1995
5. Gerken G, Teuber G, Goergen B, Meyer zum Buschenfelde F: Interferon alpha retreatment in chronic hepatitis C. J Hepatol 22S:118-121, 1995
6. Horiike N, Kurase K, Ohkura I, et al: Retreatment with interferon in chronic hepatitis C. Hepatol 21:1155-1158, 1994
7. Perano A, Testino G: Interferon therapy in chronic hepatitis. Management of non responders. Recent Progr Med 84:106-117, 1993
8. Di Bisceglie AM, Shindo M, Fong TL, et al: A pilot study of ribavirin therapy for chronic hepatitis C. Hepatology 16:649-654, 1992
9. Jouet P, Roudot-Thoraval F, Dhumeaux D, et al: Comparative efficacy of interferon alpha in cirrhotic and non cirrhotic patients with nonA nonB, C hepatitis. Gastroenterology 106:686-690, 1994
10. Schwarz R, Glaumann H, Wailand O, Norkrans G, Wejstal R, Fryden A: Interferon alpha-2b treatment of chronic post-transfusion nonA, non B, C hepatitis: Long-term outcome and effects of increased interferon doses in non responders. Scand J Infect Dis 23:413-420, 1991
11. Jacyna MR, Brooks MG, Loke RHT, et al: Randomized controlled trial of interferon alpha (lymphoblastoid interferon) in chronic nonA, nonB hepatitis. Br Med J 298:80-82, 1989
12. Castilla A, Camps J, Pilar Civeira M, et al: Lymphoblastoid alpha interferon for chronic hepatitis C: A randomized controlled study. Am J Gastroenterol 2:233-239, 1993
13. Antonelli G, Currenti M, Turriziani O, Dianzani F: Neutralizing antibodies to interferon alpha: Relative frequency in patients treated with different interferon preparations. J Infect Dis 163:882-885, 1991
14. Von Wussow P, Freund M, Blok B, Dietrich H, Poliwoda H, Deicher H: Clinical significance of anti IFN alpha antibodies titres during interferon therapy. Lancet 2:635-636, 1987
15. Milella M, Antonelli G, Santantonio T, et al: Neutralizing antibodies to recombinant alpha interferon and response to therapy in chronic hepatitis C virus infection. Liver 13:146-150, 1993
16. Dianzani F: Immunogenicity of alpha interferon. Oncol Today 7:411-416, 1992
17. Mariano TM, Donnelly RJ, Soh J, Pestka S: Structure and function of the type l interferon receptor. In Interferon: Principles and Medical Applications, 1st ed. S Baron, DH Coppenhaver, F Dianzani, et al (eds). Galveston, The University of Texas, 1992, pp 129-138
18. Ocejo OL, Schroeder BA, Lau AS: Down-regulation of interferon stimulated gene expression by UIV and tumor necrosis factor. J Interferon Res 11(S1):S107, 1991
19. Nakajima S, Kuroki T, Shioni S, Seki S, Kobayashi K: Changes in interferon receptors on peripheral blood mononuclear cell from patients with chronic hepatitis B being treated with interferon. Hepatology 12:1261-1265, 1990
20. Okada SI, Akahano Y, Suzuki H, Okamoto H, Mishico S: The degree of variability in the aminoterminal region of the E2/NS1 protein of hepatitis C virus correlates with responsiveness to interferon therapy in viremic patients. Hepatology 16:619-624, 1992
21. Finkelstein SD, Sayach R, Uchman S, Christensen S, Swalsky P: HGV undergoes extensive mutational change in NS5 region in association with relapse breakthrough following alpha-interferon therapy. Hepatology 16:132A, 1992
22. Fish EN, Banerjee K, Stehhing N: Human leukocyte interferon subtypes have different antiproliferative and antiviral activities on human cells. Biochem Biophys Res Commun 112:537-546, 1983
23. Weck PK, Apperson S, May L, Stebbing N: Comparison of the antiviral activities of various cloned human interferon-alpha subtypes in mammalian cell cultures. J Gen Virol 57:233-237, 1981
24. Orchansky P, Geren T, Rubinstein M: Isolated subtypes of human interferon-α: synergistic action and affinity of the receptor. In The Biology of the Interferon System. E De Mayer, H Schellekens (eds). Amsterdam, Elsevier Science Publ., 1983, pp 183-187
25. Interferon Alfa-N3: Physicians' GENRX: The official drug reference of FDA prescribing information and therapeutic. Equivalents 2:1145, 1993
26. Von Wussow P, Pralle H, Hochkeppel HK, et al: Effective natural interferon-α therapy in recombinant interferon-α-resistantr patients with hairy cell leukemia. Blood 78:38-43, 1991
27. Casato M, Laganà B, Antonelli G, Dianzani F, Bonomo L: Long-term results of therapy with interferon-α for type II essential mixed cryoglobulinemia. Blood 78:3142-3147, 1991
28. Von Wussow P, Jakschies D, Freund M, et al: Treatment of anti-recombinant interferon alfa2 antibody positive CML patients with natural interferon alfa. Br J Hematol 78:210-216, 1991
29. 2a. Eur J Cancer 30a: 1729-1730, 1994
30. Milella M, Santantonio T, Monno L, et al: Human leukocyte alfa interferon in the treatment of chronic hepatitis C. Medit J Infect Paras Dis 8:227-231, 1993
31. Oon CG: Long term survival following treatment of hepatocellular carcinoma in Singapore: Evaluation of Wellferon in the prophylaxis of high-risk pre-cancerous conditions. Cancer Chemother Pharmacol 31:S137-S142, 1992
32. Mazzella G, Accogli E, Sottili S, et al: Alpha interferon treatment may prevent hepatocellular carcinoma in HCV-related liver cirrhosis. J Hepatol 24:141-147, 1996